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ABSTRACT: Flavonoids represent a potential source of new antitrypanosomatidic leads. Starting from a library of natural
products, we combined target-based screening on pteridine reductase 1 with phenotypic screening on Trypanosoma brucei for hit
identiﬁcation. Flavonols were identiﬁed as hits, and a library of 16 derivatives was synthesized. Twelve compounds showed EC50
values against T. brucei below 10 μM. Four X-ray crystal structures and docking studies explained the observed structure−activity
relationships. Compound 2 (3,6-dihydroxy-2-(3-hydroxyphenyl)-4H-chromen-4-one) was selected for pharmacokinetic studies.
Encapsulation of compound 2 in PLGA nanoparticles or cyclodextrins resulted in lower in vitro toxicity when compared to the
free compound. Combination studies with methotrexate revealed that compound 13 (3-hydroxy-6-methoxy-2-(4-
methoxyphenyl)-4H-chromen-4-one) has the highest synergistic eﬀect at concentration of 1.3 μM, 11.7-fold dose reduction
index and no toxicity toward host cells. Our results provide the basis for further chemical modiﬁcations aimed at identifying novel
antitrypanosomatidic agents showing higher potency toward PTR1 and increased metabolic stability.
■ INTRODUCTION
Protozoan parasites of the Trypanosomatidae family are the
etiological agents of several signiﬁcant neglected tropical
diseases including human African trypanosomiasis (HAT),
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Chagas’ disease, and leishmaniasis, which collectively aﬀect
nearly 10 million people worldwide. HAT is caused by the
bloodstream form of Trypanosoma brucei.1 Leishmania spp.
infect macrophages and cause a wide spectrum of symptoms
ranging from cutaneous lesions to potentially fatal visceral
infections.2 Trypanosoma cruzi, the etiological agent of Chagas’
disease, is an obligate intracellular parasite that invades diﬀerent
internal organs. Since eﬀective vaccines are lacking, the control
of these diseases is based on vector control and chemotherapy.
However, the drugs currently available are characterized by high
toxicity, limited eﬃcacy, and require a long period of treatment.
The ﬁrst line drugs have been used for over half a century, and
their eﬃcacy is compromised by widespread resistance.3−5
Therefore, there is an urgent requirement for new, safe, and
eﬀective drugs. The drug discovery process against these
parasites is hampered by the intrinsic biology of these
organisms that can include intracellular stages or central
nervous system involvement.6
Although there are very few validated drug targets for
leishmaniasis and HAT, a target-based approach is extensively
used in the drug discovery process for neglected tropical
diseases.7 The folate pathway is an established target for the
treatment of bacterial infections and some parasitic diseases
such as malaria.8 Drugs targeting folate-dependent enzymes
represent useful candidates against trypanosomatidic infections
and key enzymes of the folate metabolism are thymidylate
synthase (TS) and dihydrofolate reductase (DHFR), which is
the target of the antifolate drugs methotrexate (MTX),
pyrimethamine (PYR), and trimethoprim (TMP). However,
the activity of classical inhibitors of DHFR against Leishmania
and Trypanosoma is reduced because of pteridine reductase 1
(PTR1).9 PTR1 is responsible for the salvage of pterins in
parasitic trypanosomatids and has overlapping activity with
DHFR, providing a metabolic bypass to alleviate DHFR
inhibition.10−12 Under physiological conditions, PTR1 is
responsible for only 10% of the reduction of folic acid required
by the cell, but when classic antifolate drugs inhibit DHFR, the
gene encoding the NADPH-dependent PTR1 is upregulated
and PTR1 provides the reduced folates necessary for parasite
survival.13 Therefore, PTR1 is considered a promising target for
the development of improved therapies. This protein is
considered a validated target in T. brucei, even though a
correlation between inhibition of T. brucei PTR1 (TbPTR1)
and inhibition of parasite growth has not been demonstrated
yet. The combination with MTX, a DHFR inhibitor, has been
shown to improve the eﬃcacy and the potency of PTR1
inhibitors.14,15
In the drug discovery process, natural compounds represent a
potential source of new leads.16−19 Diﬀerent natural com-
pounds from plants including ﬂavonoids have shown
antitrypanosomatidic activity.20,21 Although ﬂavonoids have
been found to inhibit polyamine biosynthesis, the mechanism
of action has not been fully elucidated.21−24 Flavonoids exert
pleiotropic eﬀects, and diﬀerent targets have been suggested to
explain at least part of their antiparasitic activity.25−27
Flavonoids have been proposed as PTR1 inhibitors only in
silico.28 Although some ﬂavonoids are very eﬀective in vitro,
they lack notable in vivo activity due to their low
bioavailability.22 However, an eﬃcient drug delivery strategy
together with a clear deﬁnition of their molecular targets could
lead to the exploitation of the antiparasitic potential of these
natural products.22
The purpose of the present study was to identify new PTR1
inhibitors showing antitrypanosomal (T. brucei, T. cruzi) and
antileishmanial (Leishmania infantum) activity by screening a
library of natural products and then by using a medicinal
chemistry approach to design, synthesize, and biologically
evaluate a new library. Assessment of early ADME and toxicity
properties provided selection criteria for further studies. MTX
has previously been combined with PTR1 inhibitors to achieve
synergistic/additive eﬀects on T. brucei.14 In our study, we
evaluated the antiparasitic activity of the compounds both alone
and in combination with MTX. Pharmacokinetic studies using
BALB/c mice showed that one of our compounds (compound
2) was characterized by a short half-life, and therefore it was
loaded in poly(lactic-co-glycolic acid) (PLGA) nanoparticles
and solubilized with cyclodextrins, aiming to increase its
stability and bioavailability.
■ RESULTS AND DISCUSSION
On-Target Screening of a Natural Product Library and
Hit Identiﬁcation. To identify potential new drugs for treating
parasitic diseases, we investigated a library of natural products.
Starting from a library of 98 compounds, a computational
docking analysis against TbPTR1 together with consideration
of structural diversity allowed the restriction of the library to 38
compounds that were tested for PTR1 inhibition. These 38
phytochemicals (NP-1−NP-38), consisting of twelve phenolic
acids, ﬁve ﬂavanones, nine ﬂavones, six ﬂavonols, two catechins,
two triterpenes, and two anthraquinones, were investigated for
in vitro inhibition of TbPTR1 and for growth inhibition of T.
brucei. Due to their ability to bind similar folate-related
metabolites, PTR1 inhibitors can also interact with other
folate-dependent enzymes such as TS and DHFR both from
parasite and human cells. Both human enzymes can be
considered potential oﬀ-targets for PTR1 inhibitors, therefore
all the compounds were assessed for their selectivity toward the
human TS and human DHFR. The data obtained are depicted
Figure 1. Activity proﬁle of the 38 phytochemicals screened against TbPTR1, hTS, and hDHFR and against the T. brucei parasite. The IC50 is
indicated by the color: dark-green, 0−30 μM; green, 31−90 μM; light-green, 90−150 μM; yellow, 151−250 μM; red, >250 μM; gray, not tested. *,
Catechins; **, triterpenes; ***, anthraquinones.
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in Figure 1. All chemical structures and IC50 values are reported
in Supporting Information, Table S1.
With the exception of quercetin dehydrate (NP-30), all
ﬂavon-3-ol type aglycones showed a signiﬁcant TbPTR1
inhibition, with 3-hydroxyﬂavone (NP-27, IC50 = 12.8 μM)
and isorhamnetin (NP-31, IC50 = 13.9 μM) being the most
potent, whereas the glycosylated ﬂavonoid (NP-32) did not
inhibit TbPTR1. Most phenolic acids showed no inhibitory
activity toward TbPTR1, highlighting the importance of a
condensed ring (chromen-4-one) for protein inhibition. The
presence of two rings, one aromatic and the other one aliphatic
(NP-8) or both aromatic (NP-10), slightly increased the
inhibitory activity with respect to the other phenolic acid
derivatives.
Figure 2. Crystal structures of TbPTR1 (gray cartoon, interacting residues in sticks) in complex with NADPH/NADP+ (in sticks, black carbon
atoms) and four inhibitors (in sticks) (A) NP-29 (cyan), (B) NP-13 (orange), (C) compound 2 (lilac), and (D) compound 7 (yellow). Hydrogen
bond interactions (dashed lines) in the active site are shown. The 2Fo − Fc electron density maps corresponding to the inhibitors (dark-blue wire)
and NADPH/NADP+ (light-blue wire), contoured at the 1σ level are shown. The chemical structures and atom names of the ligands are speciﬁed in
the insets.
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The simplest ﬂavonol (NP-27, IC50 = 12.8 μM) was 10 times
more potent than the corresponding ﬂavone (NP-18, IC50 =
120.8 μM). This implies the importance of OH at position R3.
Moreover, isorhamnetin (NP-31, IC50 = 13.9 μM) was over 35
times more active against TbPTR1 than the corresponding
ﬂavone (chrysoeriol, NP-25, IC50 > 490 μM). The insertion of
a hydroxyl group at position R5 led to a decrease in the
inhibitory activity. Indeed, the simplest ﬂavone (NP-18, IC50 =
120.8 μM) is more than 20-fold more active than primuletin
(NP-19, IC50 > 2450 μM), which has a hydroxyl group at
position 5. On target screening of the NP series indicates that
ﬂavonols are the most promising compounds, with NP-31
being the most active and selective hit (selectivity index: SI
hTS/TbPTR1 > 35; SI hDHFR/TbPTR1 = 36). Nevertheless,
a clear structure−activity relationship (SAR) could not be
established from this data set, and we could not reliably
determine how the number and the pattern of hydroxyl/
methoxy substituents inﬂuenced the activity.
The 38 compounds were also assessed for their inhibitory
activity against T. brucei parasite (Figure 1, Supporting
Information, Table S1). With the exception of NP-9, NP-10,
NP-22, and NP-35, all the natural ﬂavonoids screened showed
antitrypanosomal activity with IC50 lower than 30 μM. Figure 1
shows that there is no direct correlation between the
antitrypanosomal activity of the NP compounds and their
PTR1 inhibition eﬀect.
X-ray Crystallographic Studies of the Natural Prod-
ucts. To understand the ﬂavonoid interactions into the protein
binding site, the 18 compounds showing IC50 against TbPTR1
lower than 150 μM (compounds NP-8, NP-10, NP-12, NP-13,
NP-18, NP-21, NP-22, NP-23, NP-24, NP-26, NP-27, NP-28,
NP-29, NP-31, NP-35, NP-36, NP-37, and NP-38; Figure 1)
were selected for structural analysis. We obtained crystal
structures of the TbPTR1−NADPH/NADP+ complexes for
two moderately active natural products (NP-29 (datiscetin)
IC50 TbPTR1= 76.9 μM and NP-13 (hesperetin) IC50 = 104.2
μM) only. These compounds show inhibitory activity against
TbPTR1 and selectivity against at least one of the human
proteins (TS and DHFR; Figure 1). Statistics for data
collection and reﬁnement are reported in the Supporting
Information, Tables S2 and S3. In both cases, the crystal
asymmetric unit contains the functional unit of the enzyme, the
TbPTR1 tetramer. The tertiary structure of the TbPTR1
subunits is typical of the short-chain dehydrogenases/
reductases (SDR) superfamily and shows a single α/β domain
consisting of a seven-stranded parallel β-sheet sandwiched
between two sets of α-helices.29 The TbPTR1 active site is
mainly formed by a single chain, with one end blocked by the
C-terminus of the partner subunit. In this L-shaped depression,
the cofactor binds in an extended conformation entrapped by a
network of highly conserved hydrogen bonds.29 The substrate-
binding loop (residues 207−215) interacts with both the
cofactor and the substrate. Two surface-exposed parts of the
sequence, residues 104−112 and 143−151, are usually poorly
visible in TbPTR1 crystal structures and they were not included
in our models. The overall structure of each subunit of the
TbPTR1 complexes is the same as indicated by the small root-
mean-square deviations (RMSDs) after Cα superimposition of
the four subunits in each tetramer (0.16−0.26 Å for NP-13 and
0.11−0.41 Å for NP-29). The binding of the cofactor is
essential to create both the catalytic site and the substrate-
binding pocket, indicating an ordered sequential reaction
mechanism with NADPH binding before the substrate.30 The
pterin moiety of substrates and of pterin-like inhibitors binds in
a π-sandwich between the nicotinamide ring of NADPH/
NADP+ and the aromatic side chain of Phe97.31 Pterin also
interacts with the NADPH/NADP+β-phosphate, and this
interaction is strongly conserved in pterin-like inhibitors.31
TbPTR1-NADPH/NADP+-NP-29. The chromen-4-one core of
NP-29 binds in the biopterin binding pocket as described
above. The ligand is supported by a network of H-bonds
involving the cofactor and the surrounding residues in the
active site cavity (see Figure 2A). The hydroxyl group at
position 7 on the chromen-4-one of NP-29 (the NP-29 atom
numbering is given in the inset in Figure 2A) donates a H-bond
to the NADPH/NADP+β-phosphate and accepts a H-bond
from an amino group on Arg14. The hydroxyl group at position
5 accepts a H-bond from NADPH/NADP+ ribose OH2′ and
donates a H-bond to the hydroxyl group of Tyr174, which
donates a H-bond to the inhibitor carbonyl oxygen at position
4. Furthermore, the carbonyl oxygen and the hydroxyl group at
position 3 of NP-29 are both H-bonded to a water molecule
linked by a further H-bond to the side chain of Asp161. An
additional water molecule, which is highly conserved
throughout all TbPTR1 structures, mediates the interaction
between the position 3 hydroxyl group of NP-29 and the
backbone carbonyl oxygen of Gly205 (not shown). The o-
phenol moiety of NP-29 is located in a hydrophobic pocket of
the TbPTR1 active site cavity, surrounded by the side chains of
Val206, Leu209, Pro210, Met213, and Trp221. The 2′ hydroxyl
group on this ring is close (∼4 Å) to the carbonyl oxygen of
Gly205 and forms an intramolecular H-bond (2.4 Å) with the
hydroxyl group at position 3 of the chromen-4-one moiety.
TbPTR1-NADPH/NADP+-NP-13. The chromen-4-one core of
NP-13 also binds in the biopterin binding pocket, but it is
rotated by about 180° with respect to its orientation in the
TbPTR1−NP-29 complex (Figure 2B). The ether oxygen at
position 1 on the chromen-4-one moiety of NP-13 points
toward the side chains of Asp161 and Tyr174. The hydroxyl
group at position 7 of the NP-13 chromen-4-one is within H-
bonding distance from the NADPH/NADP+ ribose OH2′ and
the side chain of Ser95. The NP-13 hydroxyl group at position
5 accepts a H-bond from an amino group of Arg14 and donates
a H-bond to the backbone carbonyl oxygen of Leu208. The o-
methoxy-phenol (o-guaiacol) ring in position 2 on the
chromen-4-one makes a T-shaped stacking interaction with
the aromatic side chain of Trp221. Furthermore, the 3′
phenolic moiety is within H-bonding distance from the Asp161
side chain and forms two water-mediated interactions with the
backbone nitrogen of Cys168 and the amide nitrogen of
Asn175 (not shown). The methoxy oxygen at position 4′
interacts with the sulfur of the modiﬁed Cys168 (S-oxy-
cysteine), whereas the terminal methyl makes van der Waals
contacts with the side chains of Trp221 and His267 of the
partner subunit.
In summary, structural comparison of the two TbPTR1
complexes reveals two opposite orientations of the natural
ﬂavonoid inhibitors NP-13 and NP-29 in the biopterin binding
pocket in which the chromen-4-one substituents interact with
diﬀerent residues surrounding the cavity. A double binding
mode was previously observed for pteridine-like inhibitors and
MTX.15
Flavonoid Library Design and Synthesis. The crystal
structures showed that ﬂavonoids occupy the biopterin binding
site of TbPTR1, suggesting that the ﬂavonol moiety could
provide a new scaﬀold for the development of PTR1 inhibitors.
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The ﬂavonoids selected as starting points for the development
of compounds to treat trypanosomatidic diseases are depicted
in Table 1. Even though the two crystal structures showed that
the hydroxyl group at position 5 could establish H-bonds with
the protein and the cofactor, the inhibitory data on natural
ﬂavonoids (Figure 1) suggested that a hydroxyl group in this
position leads to a decrease in the inhibitory activity against
TbPTR1. Therefore, we decided to synthesize compounds with
hydroxyl substituents at positions 6 or 7 of the chromenone A-
ring because, according to the crystal structures, these should
be able to establish H-bonds with the NADPH/NADP+ ribose
and the side chain of Ser95 or with the NADPH/NADP+β-
phosphate and Arg14 (Figure 3). Moreover, we performed
modiﬁcations at positions 3′, 4′, and 5′ on ring B to explore the
SAR. As shown in Figure 3, hydroxyl groups in positions 3′, 4′,
and 5′ could form a H-bonding interaction with the Asp161
side chain and two water-mediated interactions with the
backbone nitrogen of Cys168 and the amide nitrogen of
Asn175. Many natural products have both hydroxyl and
methoxy groups, thus we synthesized and biologically evaluated
eight hydroxylated (1−8) and eight methoxylated (9−16)
compounds aiming to investigate how the number and the
pattern of hydroxyl/methoxy substituents inﬂuenced the
activity.
The synthesis of compounds 1−16 is depicted in Scheme 1.
All the compounds have been already reported in literature, but
as far as we know, they have never been proposed as PTR1
inhibitors. The intermediate chalcones (17−24) were synthe-
sized by Claisen−Schmidt condensation using substituted
acetophenones and benzaldehydes in the presence of NaOH
as the base in ethanol. The reaction was carried out as
previously reported in literature for similar compounds.26
Afterward, the chalcones (17−24) were converted into the
corresponding methoxylated ﬂavonols (9−16), using the
Flynn−Algar−Oyamada method for epoxidation and subse-
quent intramolecular cyclization of the open-chain structure.25
The reaction was performed with hydrogen peroxide in
aqueous base (1 M NaOH). Cleavage of methoxy protecting
groups with boron tribromide gave the hydroxylated ﬂavonols
1−8 in high yield. All synthesized compounds were
characterized by 1H NMR, 13C NMR, and mass analysis. The
obtained NMR and mass data are reported in the Supporting
Information (pp 33−37) and were compared with those
available in literature.
Target Compound Proﬁle. In our study, a panel of assays
was performed and activity/toxicity data were considered
during the hit selection/prioritization.32 Together with the
potency data (measured as IC50, i.e., the compound
concentration producing 50% reduction of targeted enzyme
activity and parasite cell growth), we considered the selectivity
index (IC50 toward the parasite compared with compound
cytotoxicity IC50 on host cells) and early toxicity properties. We
have assessed the entire proﬁle of the 16 synthesized
compounds, and the whole data panel has been evaluated
before selecting compounds for pharmacokinetic studies.
Testing of Synthetic Flavonols against PTR1 Enzymes.
All ﬂavonols were investigated for their activity toward T. brucei
(TbPTR1) and L. major PTR1 (LmPTR1). The results are
shown in Figure 4 and Supporting Information, Table S4. All
hydroxylated compounds except compound 5 showed sig-
niﬁcant inhibitory activity against LmPTR1 and TbPTR1 at 50
μM concentration, with compound 2 being the most potent.
Table 1. Chemical Structures and IC50 Values for Selected
Compounds from the Screened Natural Products Library
compd R5 R7 R2′ R3′ R4′
IC50
TbPTR1
(μM)
IC50 T.
brucei
(μM)
NP-27 H H H H H 12.8 9.1
NP-28 OH OH H H OH 28.0 9.0
NP-29 OH OH OH H H 76.9 27.0
NP-31 OH OH H OCH3 OH 13.9 11.2
Figure 3. Design of the synthetic library (left). NP-13 (in yellow) into TbPTR1 (in gray). The amino acids involved in the interactions of the
designed compounds are shown in diﬀerent colors. For clarity reasons, two residues involved in the interactions are not shown (Cys168 and
Asn175). Superimposition of the four crystal structures of TbPTR1 (right) (chain A gray ribbon; chain D pink ribbon; relevant active site residues as
light-blue sticks) in complex with NADPH/NADP+ (sticks, black carbon atoms) and the inhibitors (stick) NP-13 (orange), NP-29 (cyan),
compound 2 (lilac), and compound 7 (yellow). The three diﬀerent binding modes adopted by the ligands can be appreciated as well as the
movement of Trp221 (yellow sticks) upon binding of compound 7.
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Methylation resulted in almost complete loss of inhibitory
activity. The most noteworthy examples are represented by two
pairs: compounds 10 and 2 (4% and 96% inhibition of TbPTR1
at 50 μM, respectively) and compounds 12 and 4 (no
inhibition of TbPTR1 at 50 μM and 85% inhibition at 50 μM,
respectively). The introduction of a hydroxyl group on ring A
in compound 2 led to an increase of the inhibitory potency
against both enzymes of almost 3-fold with respect to
compound 1, which bears an unsubstituted ring (34%
inhibition of TbPTR1 at 50 μM). To explain a complete
SAR, X-ray crystallographic studies and docking analyses were
carried out. The compounds were evaluated also toward
TcPTR2, and none of the compounds signiﬁcantly inhibited
TcPTR2 activity (data not shown).
Crystal Structures of Synthetic Flavonoid−TbPTR1
Complexes. Compounds 2 and 7, which show inhibitory
activity against TbPTR1, were submitted to X-ray crystallo-
graphic characterization aimed at comparing their binding
poses in the PTR1 active site with those of the natural
ﬂavonoids and thus gaining further information for compound
optimization.
TbPTR1-NADPH/NADP+−2. The structure of TbPTR1 in
complex with NADPH/NADP+ and compound 2 was
determined at 1.38 Å resolution. Ligand placement and key
interactions within the active site cavity are reported in Figure
2C. Compound 2, like NP-13 and NP-29, binds in the
substrate binding pocket, with the chromen-4-one in a π-
sandwich interaction between the nicotinamide ring of
NADPH/NADP+ and the aromatic side chain of Phe97. The
chromen-4-one core of compound 2 adopts the binding mode
observed for NP-13, with the oxygen atom at position 1
directed toward the side chain of Asp161. The R6 hydroxyl
group on the chromen-4-one is within H-bonding distance
from the hydroxyl group of Ser95 and the NADPH/NADP+β-
phosphate oxygen. The carbonyl oxygen at position 4
completes the interactions made by the chromen-4-one by
receiving two H-bonds from an amino group of Arg14 and a
water molecule that is H-bonded to the NADPH/NADP+β-
phosphate O2. These interactions, together with the stacking of
the chromen-4-one described above, bring its 3 position
hydroxyl group within H-bonding distance from the backbone
Scheme 1. Synthesis of the Flavonols 1−16a
aReaction conditions: (a) NaOH (3 M), EtOH, rt; (b) H2O2, NaOH (1 M), EtOH, rt; (c) BBr3 (1 M in dry DMC), dry DMC, 0 °C → rt.
Figure 4. Inhibitory activity against TbPTR1 (in gray) and LmPTR1
(in black). The control compound was pyrimethamine, a PTR1
inhibitor (100% inhibition at 50 μM against both PTR1 enzymes).
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carbonyl oxygen of Leu208. The phenyl ring in position 2 on
the chromen-4-one establishes a T-shaped stacking interaction
with the aromatic side chain of Trp221 and forms van der
Waals interactions with the side chains of Val206 and Leu209
(not shown). The meta-hydroxyl group at the 3′ position on
the phenyl moiety of 2 is only involved in a water mediated H-
bond network linking it to the backbone carbonyl of Gly205
and the side chain of Asp161 (not shown).
TbPTR1-NADPH/NADP+−7. The structure of TbPTR1 in
complex with NADPH/NADP+ and compound 7 has been
determined at 1.76 Å resolution. Ligand placement and key
interactions within the active site cavity are shown in Figure
2D, where it can be observed that compound 7 adopts exactly
the same pose as compound 2, making the same interactions
with the enzyme and cofactor. The only diﬀerence consists in
the steric repulsion of the additional hydroxyl group at position
4′ that forces the side chain of Trp221 to move away by about
1.4 Å. The 4′ hydroxyl group is not involved in H-bonds but is
solvent exposed and presumably can form a H-bond with water.
The superposition of the four crystal structures is shown in
Figure 3. The orientation of compounds 2 and 7 in the
TbPTR1 cavity is the same as for NP-13, with the inhibitor
bicyclic core directed toward the opposite side of the cavity
with respect to NP-29. Due to the larger steric hindrance of the
substituents on the 2-o-methoxy-phenolring of NP-13, a little
rearrangement of the whole molecule occurs with a rotation of
about 35° of the bicyclic core with respect to 2 and 7 that
allows the side chain of Trp221 to remain in the position
observed in the TbPTR1−2 complex (Figure 2C). The rotation
of NP-13 allows direct H-bonding between the 3′ hydroxyl
group of NP-13 and Asp161, while the interaction of the
corresponding group of 2 and 7 is mediated by a water
molecule. The displacement of the Trp221 side chain occurring
upon binding of compound 7 can be appreciated (Trp221 as
yellow sticks in Figure 3, right).
A puzzling aspect of all four crystal structures is that the
diﬀerent inhibitors have been systematically observed bound to
three of the four TbPTR1 subunits, whereas the NADPH/
NADP+ cofactor is found bound to all subunits in three
instances out of four, although with lower occupancy in those
subunits where the inhibitor is absent. The absence of the
inhibitor is correlated with larger disorder in the substrate
binding loop that brings Trp221 into the active site cavity.
However, this loop always shows temperature factors higher
than average, even in the subunits where both cofactor and
inhibitor are bound. The disorder of this region is independent
of the crystal packing because, when the loop is disordered
(e.g., in subunit C in TbPTR1−NP-29), it approaches the
symmetry-related subunits in the same way as the ordered loop
(e.g., in subunit A in TbPTR1−NP-29) located on the opposite
face of the TbPTR1 tetramer. Conﬁrming this observation, the
other two ordered loops (e.g., in subunits B and D in
TbPTR1−NP-29) do not make close intermolecular contacts.
We can conclude that stabilization due to the π-stacking
between the R2-aromatic ring of the inhibitor and the side
chain of Trp221 is critical for the ordering of the substrate
binding loop.
Computational Docking of Synthetic Compounds to
TbPTR1 and LmPTR1 and SAR Analysis. Docking studies
were conducted to further expand the SAR to all the
hydroxylation/methoxylation patterns in the synthesized
compounds. In addition, computational docking allowed the
evaluation of possible binding modes and a corresponding SAR
for LmPTR1, for which no crystal structure with these
compounds could be solved.
Like the crystallographic studies, computational docking
showed multiple possible binding modes for the chromen-4-
one system, which roughly group into three classes: (1) a
typical substrate-like binding mode involving H-bonding with
the NADPH/NADP+ cofactor and Ser95 of TbPTR1 (or
Ser111 of LmPTR1), as observed in the complexes of
compounds 2, 7, and NP-13; (2) an alternative binding
mode with chromen-4-one ﬂipped by roughly 180° as observed
in the complex with NP-29; and (3) an inverse binding mode
solely observed in docking studies, with ring B rather than the
chromen-4-one in a stacking orientation between the NADPH/
NADP+ nicotinamide and Phe97 of TbPTR1 (or Phe113 of
LmPTR1). While three of the four crystal structures feature
binding mode (1), a general dependence of the binding mode
on the substituent pattern is notable both from crystallographic
and docking studies. In docking, many of the observed binding
modes were found to have highly similar contacts and H-
bonding partners, thus creating a favorable entropic contribu-
tion to the binding of this compound class (see also Supporting
Information, Tables S5 and S6). However, due to their large
number of H-bond donors/acceptors, ﬂavonoids can adopt
Figure 5. Comparison of the eﬀects of hydroxyl substituents at the R6 (left) and the R7 (right) positions of ring A on the binding of the synthetic
ﬂavonoids to TbPTR1. Superimposition of constraint docking poses for compound 2 (in sticks, lilac carbons) and compound 5 (in sticks, pale-green
carbons) (left) and compound 3 (in sticks, orange carbons) and compound 6 (in sticks, brown carbons) (right) in TbPTR1 (in cartoon with
interacting residues in sticks with gray carbons) in complex with NADPH/NADP+ (in sticks, black carbon atoms). A conserved water molecule is
shown in ball-and-stick representation. Hydrogen bonds are indicated by dark-gray dotted lines.
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additional binding modes with diﬀerent, often water mediated,
interactions. We therefore used a ligand constraint docking
approach to favor arrangements close to the crystal complexes
to assess the potential of other synthetic derivatives to bind in
similar orientations.
The crystal structures and docking indicate that hydrox-
ylation patterns on ring A inﬂuence the orientation of chromen-
4-one in the pocket. Precisely, compounds hydroxylated at
position R6 show diﬀerent H-bonding partners (mostly
NADPH/NADP+ phosphate and Ser95/Ser111 of TbPTR1/
LmPTR1, respectively) compared with those hydroxylated at
R7 (mostly NADPH/NADP+ ribose and Tyr174/Tyr194 or
TbPTR1/LmPTR1, respectively), see Figure 5. This diﬀerence
also aﬀected the compound activity (compare R6-hydroxylated
compound 2 (96% TbPTR1 inhibition at 50 μM) and the
corresponding R7-hydroxylated compound 3 (47% TbPTR1
inhibition at 50 μM)). While the geometry of compound 2 ﬁts
ideally in the TbPTR1 binding pocket, the slight reorientation
observed for compound 3 leads to a loss of H-bonds and
stabilizing hydrophobic contacts, halving the compound
activity. Thus, hydroxylation of ring A can ﬁne-tune the
arrangement of the chromen-4-one system within the pocket
and critically inﬂuence the interaction pattern of rings B and C.
Methoxylations, in contrast to hydroxylations, were found to
lead to activity loss. For example, the inhibitory activity against
TbPTR1 and LmPTR1 drops substantially when comparing
compound 2 with the corresponding methoxylated compound
10 (96% and 4% TbPTR1 inhibition at 50 μM; 86% and no
LmPTR1 inhibition, respectively). Methoxylations on the A-
ring cause a displacement of the chromen-4-one from the
primary stacking geometry to accommodate the bulkier
methoxy group in close proximity to the NADPH/NADP+
cofactor and Ser95 of TbPTR1 (Ser111 of LmPTR1), see
Figure 6, left. Notably, this adverse eﬀect was also apparent in
the comparison of compounds 1 and 9, bearing no substitution
on ring A but a hydroxylation or methoxylation on R3′ of the
B-ring. Whereas the activity of compound 9 is negligible,
compound 1 shows about 35% inhibition against both TbPTR1
and LmPTR1 (at 50 μM). A H-bond donor functionality on
R3′ has an important stabilizing eﬀect, as it can interact with a
water molecule bridging Asp161 and Gly205 of TbPTR1 (see
Figure 6, right) or Asp181 and Gly225 of LmPTR1. As this
water, according to our WatCH analysis, is almost 100%
conserved in both TbPTR1 and LmPTR1, it provides a clear
advantage for R3′ hydroxylated compounds. This is further
supported by the crystal structures of TbPTR1 with
compounds 2 and 7, where the R3′ hydroxylation is in H-
bonding distance to this water site. In agreement with this
observation, compound 2 with the m-hydroxyphenyl was over
30 times more active than compound 5 with a p-hydroxyphenyl
ring (96% and 3% TbPTR1 inhibition at 50 μM, respectively).
In contrast to a meta-hydroxylation, a para-hydroxylation
cannot interact with the structural water, see Figure 5. Again,
this eﬀect was sensitive to the hydroxylation pattern of ring A,
as can be observed by comparing compounds 3 (R3′ and R7
hydroxylation, 47% TbPTR1 inhibition at 50 μM) and
compound 6 (R4′ and R7 hydroxylation, 33% TbPTR1
inhibition at 50 μM), see Figure 5. While p-substituted
compounds generally show a drop in inhibitory activity
compared to their respective m-substituted counterparts, the
eﬀect is weaker for the second pair with the R7 hydroxylation
on ring A, possibly because R7 substitutions lead to a slight
rotation of the stacking chromen-4-one, directing the p-
hydroxyl toward a more solvent-exposed region of the pocket.
In conclusion, the eﬀects of individual hydroxyl substituents are
not purely local and do not show a completely additive eﬀect;
rather, the combinations of ring A and B hydroxylations will
determine the ﬁnal binding mode.
On the basis of the binding modes observed for TbPTR1, we
evaluated possible binding orientations to LmPTR1 by docking.
Notably, all compounds with R4′ hydroxylation (compounds 5
and 6), compounds with R3′ and R4′ hydroxylations
(compounds 7 and 8) and one compound with R3′
hydroxylation combined with an R7 substitution on ring A
(compound 3) were found to be slightly more active toward
LmPTR1 than TbPTR1. While the depth of the biopterin
binding pocket is well conserved and the interactions for
chromen-4-one are practically identical in both proteins, there
are notable diﬀerences in the opening of the pocket that can
explain the observed activity diﬀerences (see sequence
alignment of interaction partners in Supporting Information,
Figure S2). While in TbPTR1, R3′ hydroxylations on the B-ring
mainly come into contact with the conserved water molecule
and Cys168 (see Figure 5) and R4′ hydroxylated compounds
can hardly form direct H-bonds with the receptor, LmPTR1
generally has a more polar opening part of the pocket. Three
Figure 6. Comparison of the eﬀects of hydroxyl and methoxy substituents at the R6 (left) and the R3′ (left and right) positions on the binding of the
synthetic ﬂavonoids to TbPTR1. Constraint docking poses are shown for compound 2 (in sticks, lilac carbons), compound 10 (in sticks, dark-green
carbons) (left), compound 9 (in sticks, pale-cyan carbons), and compound 1 (in sticks, magenta carbons) (right) in TbPTR1 (in cartoon with
interacting residues in sticks with gray carbons) in complex with NADPH/NADP+ (in sticks, black carbon atoms). A conserved water molecule is
shown in ball-and-stick representation. Hydrogen bonds are indicated by dark-gray dotted lines.
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major diﬀerences are crucially important: His241, Tyr283, and
Arg287 from the neighboring subunit in LmPTR1, correspond
to Trp221, Leu263, and His267 from the neighboring subunit
in TbPTR1, thereby providing several additional polar contact
points. As the side chain of Arg287 in LmPTR1 is much bigger
than that of His267 in TbPTR1, arginine is much more
accessible to the ligands than histidine. Furthermore, as
observed in crystal structures of TbPTR1, Trp221 is rather
motile and diﬀerent rotamers lead to an open or a rather closed
form of the pocket, thereby potentially blocking ligand access to
His267. While Trp221 of TbPTR1 did not provide a H-
bonding contact to any of the studied compounds, induced ﬁt
docking studies of the compounds to LmPTR1 showed
movement of His241 to allow additional H-bonding
interactions in the most stable structure, as also shown in
Figure 7 (see also Supporting Information, Table S5). Overall,
π−π stacking and hydrophobic contacts are clearly the main
stabilizing factors for ﬂavonoids in TbPTR1, whereas a
tendency toward a higher number of H-bond donor/acceptor
contacts may stabilize hydroxylations in both the meta- and
para-positions of ring B slightly better in LmPTR1.
While addition of a para-hydroxylation for the R7 substituted
ring A did not lead to a signiﬁcant change in activity against
TbPTR1 (compound 3, 47%; compound 8, 53% TbPTR1
inhibition at 50 μM), compound 4 with hydroxylations at R3′,
R4′, and R5′ yielded a clear activity increase (85% TbPTR1
inhibition at 50 μM). Considering the lack of direct polar
contact points in TbPTR1, this is surprising and there may be
two possible explanations: (1) bridging water molecules may
enable additional contacts for the second meta-hydroxylation,
e.g., with Trp221, or (2) the compound may adopt an inverted
binding mode, placing the pyrogallol moiety in a stacking
orientation with Phe97 and the cofactor, where it could make
strong H-bonds and thereby keep the more hydrophobic
chromen-4-one in the hydrophobic TbPTR1 subpocket, where
it is able to form additional hydrophobic contacts.
Testing of Synthetic Flavonols against TbDHFR,
LmDHFR, hDHFR, and hTS. The compounds showing
inhibitory activity against PTR1 (1−8) were evaluated for
their activity against TbDHFR, LmDHFR, and hDHFR. The
results are reported in the Supporting Information, Table S7.
With the exception of compounds 1 and 2, all the tested
compounds had inhibitory activities against TbDHFR and
LmDHFR below 25% at 50 μM. Compounds 1 and 2 slightly
inhibit, respectively, TbDHFR and LmDHFR (42−43% at 50
μM). Therefore, we can conclude that compounds 1−8 have
low inhibitory activity against the parasitic DHFRs. With the
exception of compound 2, all the compounds had inhibitory
activities against hDHFR below 30% at 50 μM. The IC50 of
compound 2 against hDHFR is 50 μM and against TbPTR1 is
4.3 μM, thus compound 2 has a selectivity index higher than 10.
None of the tested compounds inhibited hTS at 50 μM (data
not shown).
Early Toxicity Studies. To characterize the compounds
properties and to deﬁne their toxicological proﬁle, we used an
assay panel typical of those employed in drug discovery projects
for hit/lead selection.32 Our panel includes hERG, ﬁve
cytochrome P450s, (CYP1A2, CYP2C9, CYP2C19, CYP2D6,
and CYP3A4), Aurora B kinase, A549 (human lung
adenocarcinoma epithelial) and WI-38 (fetal lung ﬁbroblasts)
cell lines and mitochondrial toxicity. The results of the
screening are reported in Figure 8 as a traﬃc light code
(from red through yellow to green for increasing biological
eﬀect and decreasing toxicity of the compounds) and in
Supporting Information, Table S8. An ideal lead compound
should have all parameters colored in green. In detail, the
percentage of mitochondrial toxicity and of inhibition toward
hERG, CYP isoforms, and Aurora B kinase should be below
30%, while the percentage of A549/WI-38 cells growth,
measuring cytotoxicity, should be above 70%. A few
compounds showed a percentage of inhibition toward hERG
> 10% at 10 μM. Apart from compounds 4 and 8, all the
compounds inhibited at least one isoform of cytochrome P450
(mostly CYP1A2), while only two compounds (4 and 8)
exhibited a signiﬁcant inhibitory activity against Aurora B kinase
Figure 7. Superimposition of the crystal structure of LmPTR1 (PDB
ID 1E92) in cartoon representation and interacting residues in sticks
representation. Chains A and D (containing Arg287) are colored in
pale-pink and magenta, respectively) and the best predicted receptor
conformation obtained in the induced-ﬁt docking study starting from
this crystal structure (His241 in H-bonding contact to compound 7) in
complex with NADPH/NADP+ (in sticks, black carbons) and
compound 7 (in sticks, yellow carbons). A conserved water molecule
is shown in ball-and-stick representation. Hydrogen bonds are
indicated by dark-gray dotted lines. Figure 8. Early toxicity properties combined with inhibitory activity
against T. brucei. The data are reported as a traﬃc light system. An
ideal compound (I. comp.) should have all the parameters green. The
cells are colored in green when the percentage of inhibition of T. brucei
and the percentage of A549 and W1−38 cell growth is between 60 and
100, while the percentage of inhibition of CYP isoforms, hERG,
Aurora B kinase and mitochondrial toxicity is between 0 and 30. Cells
are colored in red when data indicates toxicity or inactivity. Yellow
stands for a borderline value (30−60%): moderately active or slightly
toxic compound. Gray: not tested.
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at 10 μM. None of the compounds was either cytotoxic or
showed mitochondrial toxicity.
Testing of Synthetic Compounds on Cultured Para-
sites. With the exception of compound 8, all the molecules
were tested at 10 μM against T. brucei bloodstream form,
intracellular T. cruzi, and L. infantum intracellular amastigotes
(Figure 9). Almost all tested compounds were active against T.
brucei, while only two compounds, 4 and 12, were slightly
active against L. infantum, showing inhibitory activities of 10
and 35%, respectively. Twelve compounds (1, 2, 5−12, 14−
16) presented EC50 values against T. brucei between 1 and 8
μM (Table 2), while compounds 3, 4, and 13 showed EC50
values of 12.29, 18.04, and 20.12 μM, respectively. Only the
methoxylated compounds 10, 11, 14, and 16 showed
antiparasitic activity toward T. cruzi trypomastigotes similar to
that of nifurtimox (NFX), the reference drug for the treatment
of Chagas’ disease. Compound 10 is the most active (EC50 =
4.5 μM, NFX EC50 = 1.6 μM).
The series was assessed for cytoxicity on THP1 macrophage-
like cells to evaluate the NOAEL (no observed adverse eﬀect
level). The reference compound was pentamidine with a
NOAEL of 10 μM and a selectivity index of 6440. The
selectivity indexes of our compounds, given by the ratio
between the EC50 toward T. brucei and CC50 toward THP1,
were lower than 10 with the exception of compound 12 (SI =
17) (Table 2). The selectivity index acceptable for a compound
to be considered non toxic33 is at least 10, thus our compounds
showed slight toxicity.
Combination Studies and Evaluation of Synergy. All
compounds were evaluated in combination with MTX
independently of their PTR1 inhibitory activity against the
recombinant protein. We aimed to assess the potential gain in
potency and the reduction in toxicity through the combination
of our compounds with MTX, a well-known DHFR inhibitor.
In trypanosomatids, MTX is expected to exert a synergistic
behavior in combination with PTR1 inhibitors. Moreover,
MTX can show a synergistic eﬀect in combination with non-
PTR1 inhibitors through a multitarget inhibition. Preliminary
combination experiments in T. brucei were conducted by ﬁxing
MTX at 4 μM (MTX average EC30 against T. brucei) and
varying the concentration of the selected compounds between
1.25 and 20 μM (Supporting Information, Table S10). The
synergy coeﬃcients of all the compounds tested at the diﬀerent
concentrations (1.25, 2.5, 5, 10, 20 μM) are reported in
Supporting Information, Table S11. Eight compounds
presented a synergistic eﬀect (synergy coeﬃcient >1) when
combined with MTX. The antiparasitic activity against T. brucei
of the eight compounds both alone and in combination with
MTX is shown in Figure 10. Compounds 5, 6, and 13
consistently presented the highest synergy coeﬃcients (max-
imum synergy coeﬃcient >1.5). Compound 13 was the most
synergic with a calculated maximum synergy coeﬃcient of 3.1
at 1.25 μM (Supporting Information, Table S11). Since it
showed the highest synergy coeﬃcient together with a safe
toxicological proﬁle (Figure 8, the only poor (red) parameter is
for CYP1A2 (72% inhibition at 10 μM)), it was selected for
further synergistic combination studies.
To better evaluate the gain in potency of the combination
MTX−13, we employed the software Compusyn and a
constant ratio between the concentrations of the two
compounds chosen from their EC50 values (EC50 13 = 20
μM; EC50 MTX = 15; constant ratio = 1.3).
34 This enabled us
to quantify synergism between the two compounds (combina-
tion index, CI) and to determine the dose reduction (dose
reduction index, DRI) needed to observe the studied eﬀect in
the combination compared with the dose of each drug alone.
The combination of MTX and compound 13 at the EC50
concentration had a CI of 0.174 ± 0.047. When CI is lower
than 1, the combination can be considered synergistic,
therefore the observed CI shows strong synergism and conﬁrms
the initial data (Supporting Information, Table S10). At higher
EC values, CI becomes lower, indicating very strong synergism
(Table 3). The EC50 determined for the combination showing
CI of 0.147 was 3.15 ± 0.33 μM. This enabled an average DRI
at the EC50 of 14.6 ± 3.7 for MTX and of 11.7 ± 2.7 for
compound 13 (IC50 MTX = 1.3 μM and IC50 13 = 1.7 μM)
(Supporting Information, Figure S3C). At the EC90 of the
mixture, the predicted DRI is over 100-fold for both
compounds when compared with the EC50 of the compounds
alone. The isobologram is reported in Supporting Information,
Figure S3. The toxicity of the MTX−13 mixture on THP1 was
determined at three diﬀerent concentrations (12.5, 25, 50 μM),
and no synergistic toxicity on human cells was observed
(Supporting Information, Figure S4 and Table S12). Therefore,
the identiﬁed combination MTX−13 is selective for the
inhibition of the parasite growth, while there is no synergy in
Figure 9. Antiparasitic activity of the synthesized compounds against
Trypanosoma brucei (in gray), Trypanosoma cruzi (in green), and
Leishmania infantum (in black) at 10 μM. The reference compounds
were pentamidine (IC50 = 1.55 ± 0.24 nM) for T. brucei, miltefosine
(IC50 = 2.65 ± 0.4 μM) for L. infantum, and nifurtimox (IC50 = 2.2 ±
0.4 μM) for T. cruzi.
Table 2. EC50 against T. brucei, NOAEL, and Selectivity
Index of the Synthesized Compoundsa
compd
EC50 T. brucei (μM)
± SD
CC50 ± SD or
NOAEL
selectivity index
(CC50/EC50)
1 5.18 ± 1.10 20 4
2 7.56 ± 0.51 53 ± 2 7
3 12.29 ± 2.82 80 ± 2 6
4 18.04 ± 0.50 100 5
5 2.32 ± 0.42 20 7
6 4.29 ± 0.71 20 4
7 1.36 ± 0.57 10 6
9 2.32 ± 1.01 10 4
10 1.43 ± 0.42 10 7
11 1.14 ± 0.24 10 8
12 1.17 ± 1.07 20 17
13 20.12 ± 2.27 20 1
14 1.10 ± 0.47 10 9
15 2.02 ± 0.51 10 5
16 2.99 ± 1.86 25 8
pentamidine 0.00155 ± 0.00024 10 6440
aEC50 and NOAEL represent the arithmetic average of at least two
independent determinations done in triplicate.
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the toxicity toward the host cells. These data together with the
predicted DRI indicate that the combination improves the
selectivity indexes for both MTX and compound 13.
Pharmacokinetic Studies, in Vivo Assays, and Com-
pound Delivery. Compound 2 was selected for pharmacoki-
netic studies because it was the most active compound against
TbPTR1 (IC50 = 4.3 μM) that showed activity against the
parasite T. brucei (EC50 = 7.6 μM) and it presented a safe
proﬁle, see Figure 8. The hERG IC50 (99.3 μM) was more than
20-fold higher than the target IC50. With the exception of the
CYP1A2 IC50 (6.1 μM), the IC50 against the cytochrome
isoforms was higher than 10 μM. The solubility of compound 2
was evaluated using UV−Vis spectroscopy. In vivo bioavail-
ability and half-life of compound 2 were evaluated in BALB/c
mice treated IV with 1 mg/kg based on its low solubility. The
molecule showed a short half-life (t1/2 = 7.6 min), and it was
not detected in blood after 30 min (the plasma levels are shown
in Supporting Information, Figure S4). With the aim of
improving the plasma levels of compound 2, we used two
diﬀerent drug delivery systems: the molecule was encapsulated
in PLGA nanoparticles and solubilized with hydroxypropyl-β-
cyclodextrins. The encapsulation did not change the physical
properties of the PLGA nanoparticles as reported in Supporting
Information, Table S13. The unloaded and loaded NPs were
characterized by dynamic light scattering (DLS) in terms of
size, polydispersity index, and ζ potential. We evaluated the in
vivo bioavailability of compound 2 encapsulated in nano-
particles in BALB/c mice (IV and per os administration) and
formulated with cyclodextrins after per os administration to
NMRI mice. From preliminary data, both formulations did not
signiﬁcantly increase the levels of compound 2 in plasma
samples from mice (data not shown). However, the in vitro
activity of compound 2 both in PLGA and in cyclodextrins
solution was preserved when compared to the free compound
while the toxicity on THP1 was diminished (Table 4).
■ CONCLUSION
This is the ﬁrst study in which we have conﬁrmed the potential
of ﬂavonols as PTR1 inhibitors. Apart from compounds 4 and
8, none of the 16 synthesized ﬂavonols have previously been
reported in literature for their antiparasitic activity.22 Twelve of
these compounds show EC50 values against T. brucei below 10
μM. We performed combination studies with MTX and
compound 13, a non-PTR1 inhibitor, which was the best-
performing compound. Although the reason for the synergy is
unknown, compound 13 is an interesting compound for drug
development due to the synergistic behavior with MTX and the
low toxicity on host cells. Target identiﬁcation studies could be
carried out aiming to explain the mechanism of action. The
synthesized compounds were also evaluated for the activity
against T. cruzi trypomastigotes, and compound 10 turned out
to have a potency comparable to that of nifurtimox, the drug
currently used to treat Chagas’ disease (EC50 compound 10 =
4.5 μM, NFX EC50 = 1.6 μM). We carried out early in vitro
toxicity assays, and overall the library showed a satisfactory
proﬁle. Combining the activity/toxicity data, we selected
compound 2 for pharmacokinetic studies and we observed a
very quick turnover of the molecule in BALB/c mice. Neither
encapsulation in PLGA nanoparticles nor solubilization with
cyclodextrins increased the plasma level of compound 2;
however, both formulations allowed to maintain the in vitro
activity of the compound and to reduce the toxicity. Our crystal
structures and SAR analysis provide a basis for structure-based
drug design aimed at identifying novel ﬂavonol-like compounds
with increased potency and selectivity toward PTR1 and able to
overcome the problems of classical ﬂavonols.
■ EXPERIMENTAL SECTION
Preparation of the Natural Products Library. A library of 98
natural compounds, consisting of 8 ﬂavanones, 19 ﬂavones, 20
ﬂavonols, 2 dihydroﬂavonols, 13 anthocyanins, 2 catechins, 2
isoﬂavones, 4 chalcones, 18 phenolic acids and derivatives, 1 aurone,
5 anthraquinones, 3 triterpenes, and 1 phloroglucinol was purchased
from Extrasynthese (Genay, France) and Sigma-Aldrich-Fluka (Milan,
Italy) for drug screening. The degree of purity of all these molecules
was checked by HPLC. The HPLC analyses were performed on an
Agilent Technologies (Waldbronn, Germany) modular model 1100
system, consisting of a vacuum degasser, a quaternary pump, an
autosampler, a thermostated column compartment, and a diode array
detector (UV/DAD). The chromatograms were recorded using an
Agilent Chemstation for LC and LC-MS systems (Rev. B.01.03). An
Ascentis C18 column (250 mm × 4.6 mm I.D., 5 μm, Supelco,
Bellefonte, PA, USA) was used, with a mobile phase composed of (A)
water (H2O) and (B) acetonitrile (ACN). The gradient elution was
modiﬁed as follows: 0−3 min 25% B, 3−10 min from 25 to 30% B,
from 10−40 min from 30 to 40% B, which was held for 5 min. The
postrunning time was 5 min. The ﬂow rate was 1.0 mL/min. The
column temperature was set at 30 °C. The sample injection volume
was 5 μL. The UV/DAD acquisitions were carried out in the range
190−600 nm, and chromatograms were acquired at 310, 330, 370, and
520 nm. All the compounds tested were found to be stable, and
degradation products were not detected in the HPLC chromatograms.
Supporting Information, Table S1 shows the purity (>95%) of the 38
natural compounds screened. The natural compounds were stored at
low temperature (−80 °C), protected from light and humidity.
Computational Studies. Virtual Screening of the Natural
Product Library. The library of 98 natural products was subjected to
Figure 10. Trypanocidal activity of eight synthesized compounds alone and in combination with MTX. The compounds were tested at three
diﬀerent concentrations: 5 μM (in green), 2.5 μM (in light-pink), 1.25 μM (in light-blue). Antiparasitic activity of MTX is shown in dark-red.
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virtual screening using the GOLD software (version 5.1)35,36 following
the protocol validated in previous studies on PTR1.13 The compounds
were docked into the binding sites of the targets, LmPTR1 (PDB ID
1E92) and TbPTR1 (PDB ID 3JQ9), and the oﬀ-targets, hDHFR
(PDB ID 1U72) and hTS (PDB ID 1HVY). Ten docking poses were
generated for each ligand in each target, and these were visually
inspected and manually ranked, considering the Gold ﬁtness score,
hydrogen bonding, and π−π aromatic interactions. A search of
BioAssay data in PubChem was done to ﬁlter out promiscuous
compounds. The set of 38 compounds given in Supporting
Information, Table S1 was selected for inhibition assays considering
the above properties and structural diversity.
Docking of Synthetic Flavonoid Derivatives. The 3D structures of
the compounds were created from SMILES strings and optimized with
the OPLS_2005 force ﬁeld using Maestro.37 Ionization states and
tautomers were generated at pH 7.0 ± 0.5 using Epik.37 Up to eight
stereoisomers and one low-energy ring conformation were generated
per compound. Important structural water sites were identiﬁed using
the WatCH clustering approach.38 All available chains of the LmPTR1
crystal structures and 99 chains from TbPTR1 crystal structures (see
Supporting Information, Tables S14 and S15 for a list of structures)
were superimposed and their water sites were clustered with a distance
criterion of 2.4 Å. Water sites with at least 50% conservation were
considered conserved.
The PTR1 structures for docking consisted of chain A of the
relevant crystal structure and a C-terminal tripeptide from the
neighboring subunit pointing into the chain A active site (Val266 to
Ala268 in TbPTR1 and Thr286 to Ala288 in LmPTR1). The side
-chain oxygen atom on the modiﬁed Cys 168 in the crystal structure of
TbPTR1 was removed. Crystallographic solvent molecules were
removed and replaced by the conserved water molecules identiﬁed
by WatCH clustering. The LmPTR1 structure (PDB ID 1E92) was
aligned to the TbPTR1 template (PDB ID 5JCJ). PrepWizard was
used to assign bond orders and add hydrogen atoms.37 The N- and C-
termini of chain A were capped with N-acetyl and N-methyl amide
groups, respectively. The protonation state of the NADPH/NADP+
cofactor was computed at pH 7.0 ± 0.5. Protein protonation states
were assigned by PROPKA43 at pH 7.0. The H-bond network was
optimized and all hydrogens were subjected to a restrained
minimization. A 20 Å × 20 Å × 20 Å docking grid was centered on
Phe97 of TbPTR1 or Phe113 of LmPTR1. The following hydroxyl
groups were set rotatable: Ser95 and Tyr174 in TbPTR1 and Ser111,
Thr184, Tyr191, Tyr194, Thr195, and Tyr283 in LmPTR1, as well as
those of the NADPH/NADP+ ribose.
Docking was performed with and without ligand-based constraints
using the Glide software.39−42 For the ligand constraints, protein
preparation was performed including compound 7 (substrate-like
binding mode, PDB ID 5JCJ) or compound NP-29 (inhibitor-like
binding mode, PDB ID 5JCX) or the highest scoring docking solution
from unconstrained docking of compound 4 with ring B in a stacking
orientation (alternate binding mode). The ligands were then separated
from the structure to provide reference geometries. The van der Waals
radii of the ligand atoms were scaled by 0.80, and a partial charge
cutoﬀ of 0.15 was used. XP (extra precision) docking and ﬂexible
ligand sampling were set. Nitrogen inversions and ring conformations
were sampled, and biased sampling of torsions was performed for
amides only and set to penalize a nonplanar conformation. Epik state
penalties were added to the docking score, intramolecular H-bonds
were rewarded, and the planarity of conjugated π groups wasT
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13 Table 4. in Vitro Activity against T. brucei of Compound 2 in
Three Diﬀerent Formulationsa
preparation T. brucei EC50 (μM) THP1 CC50 ± SD or NOAEL
2 7.56 ± 0.51 53 ± 2
PLGA-2 5.70 ± 0.23 >100
cyclodextrin-2 3.27 ± 0.16 >100
aEC50 and NOAEL are the arithmetic mean of at least two
independent determinations done in triplicate.
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enhanced. A core pattern comparison with a tolerance of 3 Å was used
for the ligand-based constraint. The core was deﬁned as all non-
hydrogen atoms of the chromen-4-one core ring system except the R3
hydroxyl group. Twenty poses per ligand were subjected to
postdocking minimization with a threshold of 0.5 kcal/mol for
rejecting a minimized pose. Up to 10 ﬁnal docking solutions were
reported. Unconstrained docking was performed analogously, omitting
only the core pattern comparison. For LmPTR1, the core constraint
docking was based on the binding poses in TbPTR1. In addition,
induced-ﬁt docking was carried out using the same settings except that
the size of the docking grid was chosen automatically and a ligand and
receptor van der Waals scaling of 0.5 was applied. Reﬁnement was
carried out with Prime37 for residues within 5 Å of the ligand, followed
by XP redocking into structures within 30 kcal/mol of the best
structure and within the top 20 structures overall. Up to 20 ﬁnal
docking solutions were reported.
Synthesis. General. All commercial chemicals and solvents were
reagent grade and were used without further puriﬁcation. Reaction
progress was monitored by TLC on precoated silica gel 60 F254 plates
(Merck), and visualization was accomplished with UV light (254 nm).
1H and 13C NMR spectra were recorded on a Bruker FT-NMR
AVANCE 400. Chemical shifts are reported as δ values (ppm)
referenced to residual solvent (CHCl3 at δ 7.26 ppm, DMSO at δ 2.50
ppm, MeOD at δ 3.31 ppm); J values are given in Hz. When peak
multiplicities are given, the following abbreviations are used: s, singlet;
d, doublet; t, triplet; q, quartet; m, multiplet; br, broadened signal.
Silica gel Merck (60−230 mesh) was used for column chromatog-
raphy. All the reactions were monitored using TLC (Merck 890 F-254
silica gel). Mass spectra were obtained on a 6520 Accurate-Mass Q-
TOF LC/MS and 6310A Ion Trap LC-MS(n). The detailed NMR and
mass data of the synthesized compounds are reported in the
Supporting Information (pp 33−37).
General Procedure for the Synthesis of (2E)-1-(2-Hydroxy-
phenyl)-3-phenylprop-2-en-1-ones. An aqueous solution of NaOH
(3 M, 1.6 mL) was added to a solution of aromatic ketone (1 mmol)
and substituted benzaldehyde (1.2 equiv) in EtOH (1−2 mL). The
reaction was stirred at room temperature overnight. The reaction
mixture was cooled in an ice−water bath and acidiﬁed to pH 2 with
concentrated HCl (37%). The solid formed was ﬁltered, washed with
ethanol, and then further puriﬁed by recrystallization from EtOH.
General Procedure for the Synthesis of Methylated Flavonols
(Compounds 9−16). An aqueous solution of H2O2 (30%, 250 μL)
was added to an ice-cold suspension of the chalcone (1 mmol) in
ethanol (5 mL) and 1 M NaOH (2 mL). The mixture was allowed to
warm to room temperature and was stirred for 5−18 h. Then the
reaction mixture was cooled in an ice bath, and distilled water (2−4
mL) was added. Concentrated HCl (37%) was added until pH 2, and
the precipitate was ﬁltered, washed with EtOH, and further puriﬁed by
recrystallization from EtOH. When no precipitate occurred, the
reaction mixture was extracted with dichloromethane and washed with
water and brine. The organic layer was dried over Na2SO4 and
concentrated under reduced pressure. Column chromatography was
utilized to purify the desired product.
General Procedure for the Synthesis of Demethylated Flavonols
(Compounds 1−8). To a stirring solution of 15 (0.500 g, 1.52 mmol)
in anhydrous dichloromethane (30 mL) under nitrogen at 0 °C, boron
tribromide in dichloromethane (1.0 M, 13.7 mL, 13.7 mmol, 9 equiv)
was added. The mixture was allowed to warm at room temperature
and was stirred for 2 days. The reaction mixture was then cooled to 0
°C, and methanol (10 mL) was added. The reaction mixture was
concentrated in vacuo. Water (10 mL) was added, and the reaction
sonicated and then left to stand. Compound 7 (0.440 g, quantitative
yield) was collected as a red solid.
The procedure followed for the synthesis of all demethylated
ﬂavonols is analogue to that of compound 7 by considering 3 equiv of
BBr3 for each C−O bond cleavage.
Protein Expression and Puriﬁcation. Recombinant TbPTR1
was expressed and puriﬁed by established methods10 with minor
revisions. The plasmid was supplied by Prof. William N. Hunter,
University of Dundee. Brieﬂy, protein expression was carried out in
Escherichia coli BL21(DE3) cultured at 37 °C in SuperBroth (SB)
medium to mid log phase and induced with 1 mM isopropyl-β-D-
thiogalactopyranoside (IPTG) overnight at 30 °C.27 Cells were
resuspended in 50 mM Tris-HCl, pH 7.5, 250 mM NaCl and
disrupted by sonication. The target protein puriﬁcation was achieved
in a single step using a HisTrap FF 5 mL column (GE-Healthcare) and
an imidazole concentration of 250 mM in the same buﬀer. The
resulting protein sample was dialyzed overnight in 20 mM Tris-HCl
pH 7.5 at 8 °C (membrane cutoﬀ 10 kDa). The high purity of the
sample was conﬁrmed by SDS-PAGE analysis and MALDI-TOF mass
spectrometry. The ﬁnal protein yield of enzyme was established as
approximately 50 mg/L bacterial culture.
The plasmid pET15b-LmPTR1 was supplied by Prof. William N.
Hunter, University of Dundee. Protein expression was performed in
the E. coli strain BL21(DE3) cultured at 37 °C in SB medium
(supplemented with 100 mg/L ampicillin) to mid log phase and
induced with 0.4 mM IPTG for 16 h at 28 °C. Cells, harvested by
centrifugation, were resuspended in buﬀer A (50 mM Tris-HCl, pH
7.6, 20 mM imidazole, and 250 mM NaCl) and disrupted by
sonication. The supernatant, collected by centrifugation, was further
puriﬁed by nickel-aﬃnity chromatography (HisTrap FF 5 mL column,
GE-Healthcare), and the target protein was eluted using a 250−500
mM imidazole concentration in the same buﬀer. Fractions containing
the protein (identiﬁed by SDS-PAGE) were pooled and combined
with thrombin protease and then dialyzed overnight in 50 mM Tris-
HCl, pH 7.6, at 25 °C. The mature protein was puriﬁed by a second
nickel-aﬃnity chromatography (HisTrap FF 5 mL column, GE-
Healthcare) and eluted as weakly bound protein in 50−100 mM
imidazole and 50 mM Tris-HCl, pH 7.6. The resulting protein sample
was dialyzed in 20 mM sodium acetate pH 5.3 and 10 mM DTT. The
high purity of the sample was conﬁrmed by SDS-PAGE analysis and
MALDI-TOF mass spectrometry, and the ﬁnal protein yield
established as approximately 30 mg/L bacterial culture.
Recombinant LmDHFR-TS was cloned in our lab. The gene coding
sequence for LmDHFR-TS, cloned in pET-15b expression vector, was
introduced by thermal shock into the E. coli strain ArcticExpress-
(DE3). Bacterial culture was grown at 30 °C in ZYP-5052
autoinduction medium (supplemented with ampicillin 100 mg/L) to
OD600 nm value of about 1, and then cell growth was continued for 60 h
at 12 °C under vigorous aeration. Cells, harvested by centrifuge, were
resuspended in buﬀer A (50 mM sodium citrate pH 5.5 and 0.25 M
NaCl) and disrupted by sonication. The supernatant of the resulting
crude extract was collected by centrifuge and puriﬁed by nickel-aﬃnity
chromatography. The target protein was eluted using a linear gradient
20−250 mM imidazole in the same buﬀer. Fractions containing the
target protein (identiﬁed by SDS-PAGE) were pooled and dialyzed
overnight in buﬀer A at 8 °C. The resulting protein sample was further
puriﬁed on a gel ﬁltration column (HiLoad 16/600 Superdex 200pg,
GE Healthcare) equilibrated with 50 mM sodium citrate, pH 5.5, and
0.25 M NaCl). The high purity of the target protein was conﬁrmed by
SDS-PAGE analysis and the ﬁnal yield established as approximately 10
mg/L bacterial culture.
The recombinant TbDHFR-TS was cloned in our lab. The synthetic
gene encoding for TbDHFR-TS, optimized for E. coli expression and
cloned in pET-15b expression vector, was purchased from GenScript
USA Inc. The target protein was expressed and puriﬁed using the same
protocol described for LmDHFR-TS, with minor modiﬁcation. Brieﬂy,
cells were resuspended in buﬀer A (50 mM phosphate buﬀer, pH 7.5,
0.25 M NaCl, 10% glycerol, and 20 mM imidazole) and disrupted by
sonication. The supernatant of the resulting crude extract was
collected by centrifuge and puriﬁed by nickel-aﬃnity chromatography
(HisTrap FF 5 mL column, GE-Healthcare). The target protein was
eluted using a 400 mM imidazole concentration in the same buﬀer.
Eluted fractions were pooled and dialyzed overnight in buﬀer A at 8
°C. The resulting protein sample was concentrated and applied to a gel
ﬁltration column (HiLoad 16/600 Superdex 200pg, GE Healthcare)
equilibrated in buﬀer A. The high purity of the sample was conﬁrmed
by SDS-PAGE and the ﬁnal protein yield established as approximately
8 mg/L bacterial culture. hTS and hDHFR were puriﬁed as reported in
literature.15,44
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The kinetic characterization (Km and Kcat) of all the proteins
puriﬁed and employed for the target/oﬀ target screening is reported in
Supporting Information, Table S16.
X-ray Crystallography. Crystals of histidine-tagged TbPTR1 were
obtained by the vapor diﬀusion hanging drop method technique at
room temperature.45 Drops were prepared by mixing equal volumes of
protein (6−10 mg/mL in 20 mM Tris-HCl, pH 7.5, and 5−10 mM
DTT) and precipitant (1.5−2.5 M sodium acetate and 0.1 M sodium
citrate pH 5) solutions and equilibrated over a 600 μL reservoir. Well-
ordered monoclinic crystals grew in 3−6 days. The TbPTR1−
cofactor−inhibitor complexes were obtained by soaking crystals with
each compound solubilized either in 1,4-dioxane or DMSO (without
exceeding a dioxane-DMSO/crystal solution ratio of 1:9). After 4−21
h, crystals were transferred to a cryoprotectant, prepared by adding
30% v/v glycerol to the precipitant solution, and ﬂash frozen in liquid
nitrogen. Diﬀraction data for the complexes with compound NP-29
and NP-13 were measured using synchrotron radiation at the
Diamond Light Source (DLS, Didcot, United Kingdom) beamline
I04 equipped with a Pilatus 6M-F detector, using a wavelength of
0.9795 Å, a 0.25° rotation, and a 0.4 s exposure time/image. Data for
the complex TbPTR1-NADPH/NADP+−2 were collected at the DLS
beamline I03 equipped with a Pilatus3 6 M detector and using a
wavelength of 0.9173 Å, a 0.25° rotation, and a 0.15 s exposure time/
image. Data relative to the complex with compound 7 were collected
at the European Synchrotron Radiation Facility (ESRF, Grenoble,
France) beamline ID30A-1, equipped with a Dectris Pilatus3 2 M
detector and by using a wavelength of 0.9660 Å, a 0.1° rotation, and a
0.08 s exposure time/image. X-ray images were integrated using
Mosﬂm and scaled with SCALA within the CCP4 software suite.46−48
TbPTR1 crystals belong to the monoclinic space group P21, showing
only slight variations in cell parameters among the diﬀerent crystals.
Data collection and processing statistics are reported in Supporting
Information, Table S2. The structures were solved by molecular
replacement using the software Molrep49 and a whole tetramer of
TbPTR1 (PDB code 2X9G) as searching model.50 Structural models
were reﬁned using REFMAC5,51 whereas the program Coot52 was
used for electron density inspection, model manipulation, and
placement of the solvent molecules. The ﬁnal models were inspected
manually and checked with the programs Coot and Procheck.53 Data
reﬁnement statistics are reported in Supporting Information, Table S3.
Figures were generated with CCP4 mg.54
TbPTR1, LmPTR1, TbDHFR, LmDHFR, hTS, and hDHFR Target
Enzyme Assays. The in vitro assay used for PTR1 enzymes is based
on the coupled assay reported by Shanks et al.55 PTR1 uses H2B as a
substrate and requires also NADPH for the reaction, and the reduction
of H2B to H4B by PTR1 is nonenzymatically linked with the
reduction of cytochrome c in this assay, which is detected at 550 nm.
The formation of cyt c Fe2+ results in a signal increase in the
photometric readout.
TbPTR1 and LmPTR1 activity was assayed in a buﬀer containing 20
mM sodium citrate (pH 6.0). The ﬁnal reaction mixture contained the
test compound at a range of concentrations and TbPTR1/LmPTR1
(6.0 nM/12 nM), H2B (0.3 μM/3 μM), cytochrome c (100 μM/100
μM), and NADPH (500 μM/500 μM). The ﬁnal assay volume was 50
μL in 384-well clear plates (Greiner Bio-One, 781101). Compound
screening was performed by addition of compound to assay plates (in
100% DMSO) followed by addition of 45 μL of Reaction Mix
(enzyme, H2B cytochrome c in 20 mM sodium citrate buﬀer). A
preread was made at 550 nm using an EnVision Multilabel Reader
2103 (PerkinElmer Inc., US), followed by incubation of the assay
plates at 30 °C for 10 min. The reaction was initiated by the addition
of 5 μL of NADPH (5 mM in ultrapure water), followed by the
kinetically reading of the assay plates at 550 nm using the EnVision
MultilabelReader at 10, 20, 30, 40, and 50 min, and the slope of each
assay well was calculated. The screening data was analyzed using
ActivityBase (IDBS) and for outlier elimination in the control wells
the 3-σ method was applied. On the basis of the slope, data was
normalized to the positive control methotrexate for TbPTR1/
LmPTR1 (1 μM/50 μM, yielding 100% inhibition) and negative
controls (1% DMSO, yielding 0% inhibition) and % inhibition
calculated for all samples. The measurement at time 0 min was used to
ﬂag optically interfering samples. Each compound was tested in
triplicate and the pIC50 value, standard deviation, Hill slope, minimum
signal, and maximum signal for each dose−response curve were
obtained using a four-parameter logistic ﬁt in the XE module of
ActivityBase (IDBS).
LmDHFR, hDHFR, and hTS activities were assessed spectrophoto-
metrically.13 The Km for the substrates and kcat for all enzymes puriﬁed
and used for the inhibition studies are reported in Supporting
Information, Table S16.
In Vitro Biological Assays. A cloned line of L. infantum (MOM/
MA671TMAP263) promastigotes were maintained in RPMI 1640
medium supplemented with 10% heat-inactivated fetal bovine serum
(FBS), 2 mM L-glutamine, 20 mM HEPES, and 1% Penn/Strep.
Maintenance of promastigotes was done in T-25 ﬂasks at 26 °C by
subpassage at 106 parasites/mL every 5−6 days. L. infantum axenic
amastigotes expressing episomal luciferase were maintained in MAA/
20 (axenic amastigote medium) at 37 °C under a 5% CO2
environment with subpassages every 5 days. LUC-positive parasites
were selected by addition of Geneticin sulfate (G418) to the culture at
60 μg/mL. Trypanosoma brucei brucei Lister 427 bloodstream forms
were grown at 37 °C, 5% CO2 in complete HMI-9 medium
supplemented with 10% fetal calf serum (FCS) and 100 UI/mL of
penicillin/streptomycin. Cultures were diluted before a cell density of
2 × 106/mL was reached.
In Vitro Evaluation of Activity against L. infantum Intra-
macrophage Amastigotes. The eﬃcacy of compounds against L.
infantum intracellular amastigotes was determined according to
literature56 but with slight modiﬁcations. Brieﬂy, 1 × 106 THP-1-
derived macrophages were infected with luciferase-expressing L.
infantum axenic amastigotes in a macrophage:amastigotes ratio of
1:10 for 4 h at 37 °C, 5% CO2. Noninternalized parasites were washed,
and compounds were added at diﬀerent concentrations (20−0.6 μM).
After 72 h of incubation at 37 °C and 5% CO2, media was substituted
by PBS. Macrophages were lysed by addition of 25 μL of Glo-lysis
buﬀer (Promega). Steady-Glo reagent (Promega) was then added, and
the content of each well was transferred to white-bottom 96-well
plates. Luminescence intensity was read using a Synergy 2 multi-mode
reader (Biotek). The antileishmanial eﬀect was evaluated by the
determination of IC50 value (concentration required to inhibit growth
in 50%) and calculated by nonlinear regression analysis using
GraphPad Prism version 5.00 for Windows, GraphPad Software, San
Diego, California, www.graphpad.com.
In Vitro Evaluation of Activity against T. brucei. The eﬃcacy of
compounds against T. brucei bloodstream forms was evaluated using a
modiﬁed resazurin-based assay previously described.57 Mid log
bloodstream forms were added to an equal volume of serial dilutions
of compounds in supplemented complete HMI-9 medium at a ﬁnal
cell density of 5 × 103/mL. Following incubation for 72 h at 37 °C 5%
CO2, 20 μL of a 0.5 mM resazurin solution was added and plates were
incubated for further 4 h under the same conditions. Fluorescence was
measured at 540 and 620 nm excitation and emission wavelength,
respectively, using a Synergy 2 multi-mode reader (Biotek). The
antitrypanosomatid eﬀect was evaluated by the determination of IC50
value (concentration required to inhibit growth in 50%) and calculated
by nonlinear regression analysis using GraphPad Prism version 5.00
for Windows, GraphPad Software, San Diego California, www.
graphpad.com. Half-maximal inhibitory concentrations (IC50) reported
correspond to the averages of the results obtained in at least two
independent experiments. Compusyn software 1.0 was used to
evaluate synergy.34
In Vitro Evaluation of Activity against T. cruzi. Infections were
performed in 6-well plates (3 × 106 HG39 cells/well). Conﬂuent
HG39 cells were infected with sanguineous trypomastigotes of T. cruzi
Y strain at a 1:1 ratio. After 4 h, the cells were washed three times with
PBS and fresh medium was added (RPMI supplemented with Glut/
Pen/Strep and 20% heat-inactivated FCS, Sigma-Aldrich). The
infected cells were incubated at 37 °C and 5% CO2). Then 24 h
post infection, the cells were treated with compounds and incubation
was continued for 48 h. The gDNAs of infected cells were isolated
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using the LGC Genomics Mag Maxi kit following the manufacturer’s
(LGC Genomics, Berlin) protocol and used as a template for a
TaqMan probe-based quantitative real-time PCR.58 The reference
gene and the gene of interest were ampliﬁed using the KAPA Probe
Fast qPCR Master Mix Kit (VWR) following the manufacturer
protocol. Template DNA was used as 10% of the ﬁnal reaction
volume. Primers speciﬁc for human β-actin (reference gene) were
human-β-AcF2 (CCCATCTACGAGGGGTATG) and human-β-
AcR3 (TCGGTGAGGATCTTCATG). The parasite actin-speciﬁc
primers were T. cruzi-AcF (CGTGAGAAGATGACACAG) and T.
cruzi-AcR (GGGAGAGAGTATCCCTCG). All primers were used at
a ﬁnal concentration of 300 nM. The probe-speciﬁc for human β-actin
was human-β-Ac probe (Cy5-CCTGGCTGGCCGGGACCTGAC-
BHQ-3) labeled with the dye Cy5 at the 5′end and with the quencher
BHQ-3 at the 3′ end. The probe speciﬁc for parasite actin was T. cruzi
Ac probe (FAM-CACGCCATCACCAGCATCAAG-BHQ-1) labeled
with the dye FAM at the 5′ end and with the quencher BHQ-1 at the
3′ end. Probes were used in a ﬁnal concentration of 200 nM. The
program was adapted to the use with the KAPA Probe Fast qPCR
Master Mix Kit.
Cytotoxicity Assessment against THP-1 Macrophages. The
eﬀect of compounds 1−16 on THP-1-derived macrophages was
assessed by the colorimetric MTT assay (3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyl tetrazolium bromide). Brieﬂy, 1 × 106 THP-1 cells were
diﬀerentiated into macrophages by addition of 20 ng/mL of phorbol-
myristate 13-acetate (PMA, Sigma-Aldrich) for 18 h, followed by
replacement with fresh medium for 24 h. Cells were incubated with
compounds ranging from 100 to 3 μM after dilution in RPMI
complete medium containing a maximum amount of 1% DMSO. After
incubation for 72 h at 37 °C, 5% CO2, medium was removed and a 0.5
mg/mL MTT solution was added. Plates were incubated for additional
4 h to allow viable cells to convert MTT into a purple formazan
product. Solubilization of formazan crystals was achieved by addition
of 2-propanol, and absorbance was read at 570 nm using a Synergy 2
multi-mode reader (Biotek). Cytotoxicity was evaluated by the
determination of CC50 value (drug concentration that reduced the
percentage of viable cells in 50%) and calculated by nonlinear
regression analysis using GraphPad Prism version 5.00 for Windows,
GraphPad Software, San Diego California, www.graphpad.com.
hERG Cardiotoxicity Assay. The Invitrogen Predictor hERG
ﬂuorescence polarization assay was used in 384-well assay format
(Greiner Bio-One, 784076) to test compounds. To each well of the
assay plate, 100 nL of the test/control compound was added followed
by addition of 5 μL of homogenized membrane solution (undiluted),
followed by a further addition of 5 μL of tracer (1 nM ﬁnal
concentration in assay). The plates were incubated for 2 h at 25 °C in
a humidity controlled incubator and the ﬂuorescence polarization
measured using an EnVision multilabel reader 2103 (Perkin Elmer
Inc., US). The screening data was analyzed using ActivityBase (IDBS),
and for outlier elimination in the control wells the 3-σ method was
applied. The negative controls (0% inhibition) and positive controls E-
4031, a blocker of hERG-type potassium channels (yielding 100%
inhibition), were used to normalize the raw data. Each compound was
tested in triplicate, and the pIC50 value, standard deviation, Hill slope,
minimum signal, and maximum signal for each dose−response curve
were obtained using a four-parameter logistic ﬁt in the XE module of
ActivityBase (IDBS). All IC50 data were associated with <10% SD.
Cytochrome P450 1A2, 2C9, 2C19, 2D6, and 3A4 Assay. The
luminescence based P450-Glo (Promega) was used in 384-well assay
format (Greiner Bio-One, 784076) to test compounds. The selected
cytochrome P450 panel included microsomal preparations of
cytochromes P450 1A2, 2C9, 2C19, 2D6, and 3A4 (Corning) from
baculovirus infected insect cells (BTI-TN-5B1−4) which express
cytochromes P450 (CYP) and cytochrome c reductase (and
cytochrome b5 for 3A4). Compounds/controls were added into the
empty 384-well plate (100 nL/well v/v 100% DMSO) using the Echo
550 Liquid Handler (Labcyte Inc., US), followed by addition of 5 μL/
well of CYP/Luciferin substrate, and incubated for 30 min at 37 °C.
The reaction was initiated by addition of 5 μL/well NADPH
regeneration mixture. After 30 min at 37 °C, the CYP reaction was
stopped and the luciferase reaction was initiated by addition of 10 μL/
well of luciferin detection reagent. After additional 30 min at 37 °C,
the luminescence readout was performed using the Inﬁnite M1000
PRO plate reader (Tecan). Outliers in the control wells were
eliminated according to the 3-σ method. Negative controls (0%
inhibition) included only vehicle (v/v 1% DMSO), standard speciﬁc
CYP inhibitors [CYP 1A2 inhibitor α-naphtho-ﬂavone (Sigma-Aldrich,
15 nM), CYP 2C9 inhibitor sulfaphenazole (Sigma-Aldrich, 67 nM),
CYP 2C19 inhibitor troglitazone (Sigma-Aldrich, 3.2 μM), CYP 2D6
inhibitor quinidine (Sigma-Aldrich, 2 nM), and CYP 3A4 inhibitor
ketoconazole (Sigma-Aldrich, 54 nM)] were used as positive controls
(100% inhibition). Each compound was tested in triplicate, and the
pIC50 value, standard deviation, Hill slope, minimum signal, and
maximum signal for each dose−response curve were obtained using a
four-parameter logistic ﬁt in the XE module of ActivityBase (IDBS).
All IC50 data were associated with <10% SD.
Cytotoxicity Assay against A549 and WI38 Cells. These assays
were performed using the CellTiter-Glo assay from Promega Corp.
A549 cells obtained from DSMZ (German Collection of Micro-
organisms and Cell Cultures, Braunschweig, Germany) and WI-38
cells were obtained from ATCC (ATCC CCL-75) and were grown on
surface modiﬁed T175 cell culture ﬂasks (cat. no. 660175, Greiner Bio-
One GmbH, AT) in DMEM (cat. no. 41966−052, Life Technologies,
US) with 10% FCS, streptomycin (100 μg/mL) and 100 U/mL
penicillin G (cat. no. P-11-010, PAA Laboratories GmbH, AT). Cells
were incubated at 37 °C in the presence of 5% CO2 and were
harvested at 80−90% conﬂuency. Each test compound (200 nL of 10
mM in 100% v/v DMSO) was added to polystyrene 384-well cell
culture microtiter plates (cat. no. 781073, 384 CellStar, Greiner Bio
One, AT) using the Echo 550 Liquid Handler (Labcyte Inc., US). To
harvest the cells, 1.5 mL of trypsin/EDTA (cat. no. L11-004, 0.5 and
0.22 mg/mL, respectively, PAA Laboratories GmbH, AT) was added
per T175 ﬂask and incubated at 37 °C in the presence of 5% CO2 for 2
min. Detached cells were then resuspended in prewarmed media to a
density of 0.2 × 106 cells/mL. From this cell suspension, 20 μL was
added per well of a 384-well microtiter plate, thereby giving a ﬁnal test
compound concentration of 100 μM and 0.1% v/v DMSO. After 48 h
of incubation at 37 °C in the presence of 5% CO2, 20 μL of CellTiter-
Glo reagent (cat. no. G7571, Promega Inc., US) was added per well
and the plate placed upon a linear shaker for 1 min at room
temperature and further incubated at room temperature without
shaking for 10 min. The luminescence readout was performed using
the EnVision multilabel reader 2103 (PerkinElmer Inc., US) with a 0.5
s read time per well. Each assay plate also contained 16 wells for the
positive control (cells prepared by treatment with cisplatin: 200 nL of
300 mM stock solution in 100% v/v DMSO, giving a ﬁnal
concentration of 3 mM cisplatin). The 16 wells for the negative
controls per assay plate were prepared by treatment of cells with
DMSO only (200 nL). Each compound was tested in triplicate, and
the pIC50 value, standard deviation, Hill slope, minimum signal, and
maximum signal for each dose−response curve were obtained using a
4-parameter logistic ﬁt in the XE module of ActivityBase (IDBS).
Assessment of Mitochondrial Toxicity. The 786-O (renal
carcinoma) cell line was used for mitochondrial toxicity screening.
Cells were maintained using RPMI-1640 medium containing 2 mM
glutamine, 100 U/mL penicillin G, 100 mg/mL streptomycin, and
10% FCS. Cells were counted and diluted to a concentration of 75000
cells/mL, and 20 μL of this suspension (1500 cells/well) were added
to Cell Carrier 384-well TC plates (PerkinElmer Inc.) and incubated
for 36 h at 37 °C and 5% CO2. Compound dilutions were prepared
using a 384-well PP predilution plate (Greiner Bio-One), and 20 μL of
the dilution were transferred to the 786-O cells. The low controls were
valinomycin (ﬁnal concentration of 1 μM and 1% DMSO v/v in
column 23) and the high controls were 1% DMSO v/v in column 24.
After 6 h incubation at 37 °C and 5% CO2, 10 μL of a 200 nM
solution of MitoTracker Red CMXRos (ﬁnal concentration 50 nM) in
prewarmed cell culture media (RPMI-1640 supplemented with 10%
FCS, 100 U/mL penicillin, and 100 μg/mL streptomycin) was added
to each well and the 786-O cells were incubated for an additional 45
min at 37 °C and 5% CO2. MitoTracker Red CMXRos uptake was
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measured using an Opera HCS system (PerkinElmer), and image
analysis was performed using Columbus 2.4.0 (Perkin Elmer). All
screening experiments were performed for the compounds as 11-point
dose−responses in triplicates. The raw data were processed using
GraphPad Prism (GraphPad Software Inc.), with outliers in control
wells eliminated according to the 3-σ method. The dose−response
curves were analyzed using four-parameter sigmoidal ﬁt to obtain
plausible results in the case of nonsigmoidal dose−response curves.
Aurora B Kinase Assay. The assay used was the ADP-Glo Kinase
Enzyme System from PromegaCorp. The assay was performed in 384-
well white low volume plate (Corning Inc., NY, 3824). The control
compound used was SU6656 (Calbiochem, Germany, 572635) at a
ﬁnal concentration of 1 μM in column 23 and DMSO in column 24 at
the same concentration (v/v) as the SU6656 control and the
compound area. DMSO concentration is tolerated up to 2% ﬁnal (v/
v). An enzyme Mastermix containing 1× buﬀer, 50 μM DTT, and 17.5
ng/μL (35 μL/well) Aurora B [all reagents provided in the kit] was
prepared. A substrate Mastermix containing 1× buﬀer, 36 μM ATP,
and 7.5 ng/μL (15 ng/well) MBP protein as substrate [buﬀer, MBP
provided in the Aurora B Kinase Enzyme System kit; ultrapure ATP
provided in the ADP-Glo Kinase Assay kit] was prepared. Then 2 μL
of the enzyme Mastermix and 2 μL of the substrate Mastermix were
added to each well of a 384 low volume plate, and the plate was sealed
using Thermowell sealing tape (Corning Inc. NY, USA) and incubated
for 45 min at RT. The enzymatic reaction was stopped by adding 4 μL
of ADP-Glo reagent [provided in the ADP-Glo Kinase Assay kit], and
the plate is sealed again using Thermowell sealing tape (Corning Inc.
NY) and incubated for 40 min at RT. Afterward, 8 μL of detection
reagent were added to each well and the plate was sealed again. The
plate was incubated for 45 min at RT, and afterward luminescence was
measured using the EnVision multilabel reader 2103 (Perkin Elmer
Inc., US). Each compound was tested in triplicate, and the pIC50 value,
standard deviation, Hill slope, minimum signal, and maximum signal
for each dose−response curve were obtained using a four-parameter
logistic ﬁt in the XE module of ActivityBase (IDBS). All IC50 data were
associated with <10% SD.
Solubility Assays. UV−visible spectroscopy was used to measure
the solubility of compound 2. The experiments were carried out with
the instrument CARY 50. Six diﬀerent solutions (3.125, 6.25, 12.5, 25,
50, and 100 μM) were prepared. The maximum of absorbance was
found at 334 nm, and epsilon was calculated. Four saturated solutions
were prepared: 100 μM in water, 100 μM in PBS, 200 μM in PBS +
10% DMSO, and 10 mM in PBS + 50% DMSO. The suspensions were
left in incubation at 25 °C for 18 h, then ﬁltered (0.2 μm). The
absorbance at 334 nm was measured. One blank and three replicates of
the same sample were performed for each solution. Using the
calibration curve (Y = 0.0143x + 0.0033), we calculated the maximum
solubility. Maximum solubility in water: 2.6 μM. Max solubility in PBS:
0.5 μM. Max solubility in PBS + 10% DMSO = 85.5 μM. Max
solubility in PBS + 50% DMSO = 7.0 mM.
Compound 2 Encapsulation in PLGA and Solubilization with
Cyclodextrins. The encapsulation of compound 2 on PLGA
nanoparticles was obtained by a nanoprecipitation methodology.
The polymer was dissolved in acetone at 20 mg/kg to for the diﬀusing
phase. Then 0.5 mg of free compound were added for drug loading.
This phase was then added to 10 mL of Pluronic F127 (0.1% in water)
under moderate magnetic stirring at room temperature. For the
evaporation of the organic solvent, the emulsion was stirred for 2 h.
The formed NPs were recovered and washed by centrifugation and
stored in PBS at 4 °C until use. Quantiﬁcation of incorporated
compound was done by the indirect method using absorption
spectrophotometry. Standard curves for each compound were
performed using 334 nm. The encapsulation eﬃciency was calculated
as the ratio between the initial quantity of compound added to
produce the NPs and the quantity of nonencapsulated compound
present in the recovery and washing supernatants over the initial
quantity of compound added to produce the NPs. Particles were
characterized by dynamic light scattering (DLS); the size, polydisper-
sity index, and ζ potential were determined using a Zetasizer Nano ZS
(Malvern Instruments, Malvern, UK) with a detection angle of 173°.
Measurements were made in triplicate at 25 °C. Compound 2 was
solubilized with hydroxypropyl-β-cyclodextrin (50% w/vol)/(Cavasol
W7 HP Pharma, Ashland).
Pharmacokinetics of Compound 2. Plasma samples from 6
BALB/c mice treated with compound 2 administered alone (1 mg/kg
IV) (5, 15, and 30 min post administration, pa), in PLGA
nanoparticles (1 mg/kg/IV and oral) (0, 5, 15, 30, 45, 60 min and
then 1 min, 3 min, 24 h, 48 h, and 72 h pa) and solubilized with
cyclodextrins (NMRI mice, 4 mg/kg/per os) (1, 6, and 24 h pa) were
analyzed by HPLC. Analysis was carried out with a modular Jasco
HPLC ﬁtted with a Hypersil BDS C18 column (250 mm × 4.6 mm, 5
μm) (Thermo Scientiﬁc) as stationary phase. Samples were treated
with acetonitrile (ACN), vortexed, centrifuged (15 min, 6000 rpm),
ﬁltered through a 0.45 μm ﬁlter (Pall GHP Acrodisc GF), and assayed.
Mobile phase was ACN:pure water (35:65), ﬂow rate was 1.5 mL/min,
injection loop was 100 μL, and detection at a wavelength of 335 nm.
Sulfate and glucuronide conjugation of compound 2 was tested.59
Ethics Statement. All experiments performed at IBMC were
carried out in accordance with the IBMC and INEB Animal Ethics
Committees and the Portuguese National Authorities for Animal
Health guidelines, according to the statements on the directive 2010/
63/EU of the European Parliament and of the Council.
The experimental design and housing conditions at UCM were
approved by the Committee of Animal Experimentation (Universidad
Complutense de Madrid) and regional authorities (Community of
Madrid) (ref. PROEX 169/15). Experiments were carried out at the
animal house with oﬃcial identiﬁcation code ES280790001164
following the 3Rs principles. Animal handling and sampling were
performed by trained and oﬃcially qualiﬁed personnel.
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